Transforming Coherus Adds To IO Pipeline Via Merger With Surface Oncology

 
• By Joseph Haas

Currently battling AbbVie over pricing plans for its Humira biosimilar, Coherus is also looking to become an immuno-oncology player, acquiring two more clinical assets in an all-stock deal.

Merger
Coherus/Surface merger would result in pipeline with four clinical IO candidates • Source: Shutterstock

More from Deals

More from Business